BioLux
The micro format does not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.
Balance sheet
balance sheet total €12,481 on 31-12-2025in euro
in euro
Position in the sector
25.2%
Higher than 43% of the 25,388 companies filing micro accounts in retail trade (NACE 47) in 2025.
1.33
Higher than 46% of the 24,385 companies filing micro accounts in retail trade (NACE 47) in 2025.
-99.4%
Lower than 95% of the 24,575 companies filing micro accounts in retail trade (NACE 47) in 2025.
Net result: bottom quarter · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 202313 months |
|---|---|---|---|---|
| - | - | 91 | ||
| -12,884 | 4,074 | - | ||
| 3,049 | 15,458 | 11,312 | ||
| 25.2% | 58.9% | 56.6% | ||
| 1.33 | 2.43 | 2.30 | ||
| 2.97 | 0.70 | 0.77 | ||
| -395.2% | 26.7% | 64.9% | ||
| -99.4% | 15.7% | 36.8% |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 202313 months |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
12,481 | 26,383 | 20,134 | |
21/28 |
91 | 91 | 91 | |
28 |
91 | 91 | 91 | |
29/58 |
12,390 | 26,292 | 20,043 | |
40/41 |
8,954 | 9,972 | 7,797 | |
40 |
7,647 | 5,590 | 3,820 | |
41 |
1,307 | 4,382 | 3,977 | |
54/58 |
3,436 | 16,320 | 12,246 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
12,481 | 26,383 | 20,134 | |
10/15 |
3,140 | 15,549 | 11,402 | |
10/11 |
4,000 | 4,000 | 4,000 | |
13 |
- | 11,549 | 7,402 | |
133 |
- | 11,549 | 7,402 | |
14 |
-860 | - | - | |
17/49 |
9,341 | 10,834 | 8,731 | |
42/48 |
9,341 | 10,834 | 8,731 | |
44 |
7,219 | 5,088 | 2,414 | |
440/4 |
7,219 | 5,088 | 2,414 | |
45 |
2,122 | 5,113 | 5,669 | |
450/3 |
2,122 | 5,113 | 3,169 | |
454/9 |
- | - | 2,500 | |
47/48 |
- | 632 | 648 | |
| Income statement | ||||
9900 |
-11,436 | 6,580 | 12,356 | |
640/8 |
767 | 472 | 1,676 | |
9901 |
-12,203 | 6,108 | 10,680 | |
75/76B |
32 | 50 | - | |
75 |
32 | 50 | - | |
65/66B |
59 | 68 | 108 | |
65 |
59 | 68 | 108 | |
9903 |
-12,231 | 6,090 | 10,572 | |
67/77 |
178 | 1,944 | 3,169 | |
9904 |
-12,409 | 4,146 | 7,402 | |
9905 |
-12,409 | 4,146 | 7,402 | |
| Appropriation of the result | ||||
9906 |
-12,409 | 4,146 | 7,402 | |
791/2 |
11,549 | - | - | |
691/2 |
- | 4,146 | 7,402 | |
6921 |
- | 4,146 | 7,402 | |
| Document | ||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 19-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankInvestments
fixed assets acquired| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Financial fixed assets | - | - | €91 |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on BioLux
The operating result for 2025 is a loss of €12,203, after a profit of €6,108 in 2024.
Debt's share of the balance-sheet total rises from 41.1% to 74.8%. Equity and debt are lower.